These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 30819766

  • 1. A Serial 10-Year Follow-Up Study of Atrophied Brain Lesion Volume and Disability Progression in Patients with Relapsing-Remitting MS.
    Zivadinov R, Horakova D, Bergsland N, Hagemeier J, Ramasamy DP, Uher T, Vaneckova M, Havrdova E, Dwyer MG.
    AJNR Am J Neuroradiol; 2019 Mar; 40(3):446-452. PubMed ID: 30819766
    [Abstract] [Full Text] [Related]

  • 2. Atrophied Brain Lesion Volume: A New Imaging Biomarker in Multiple Sclerosis.
    Dwyer MG, Bergsland N, Ramasamy DP, Jakimovski D, Weinstock-Guttman B, Zivadinov R.
    J Neuroimaging; 2018 Sep; 28(5):490-495. PubMed ID: 29856910
    [Abstract] [Full Text] [Related]

  • 3. A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis.
    Tavazzi E, Bergsland N, Kuhle J, Jakimovski D, Ramanathan M, Maceski AM, Tomic D, Hagemeier J, Kropshofer H, Leppert D, Dwyer MG, Weinstock-Guttman B, Benedict RHB, Zivadinov R.
    J Neurol; 2020 Mar; 267(3):802-811. PubMed ID: 31768628
    [Abstract] [Full Text] [Related]

  • 4. Diffusion tensor imaging reveals greater microstructure damage in lesional tissue that shrinks into cerebrospinal fluid in multiple sclerosis.
    Bergsland N, Dwyer MG, Jakimovski D, Weinstock-Guttman B, Zivadinov R.
    J Neuroimaging; 2021 Sep; 31(5):995-1002. PubMed ID: 34081373
    [Abstract] [Full Text] [Related]

  • 5. Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis.
    Genovese AV, Hagemeier J, Bergsland N, Jakimovski D, Dwyer MG, Ramasamy DP, Lizarraga AA, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R.
    Radiology; 2019 Nov; 293(2):424-433. PubMed ID: 31549947
    [Abstract] [Full Text] [Related]

  • 6. Assessment of T2 lesion-based disease activity volume outcomes in predicting disease progression in multiple sclerosis over 10 years.
    Oship D, Jakimovski D, Bergsland N, Horakova D, Uher T, Vaneckova M, Havrdova E, Dwyer MG, Zivadinov R.
    Mult Scler Relat Disord; 2022 Nov; 67():104187. PubMed ID: 36150263
    [Abstract] [Full Text] [Related]

  • 7. Feasibility of Brain Atrophy Measurement in Clinical Routine without Prior Standardization of the MRI Protocol: Results from MS-MRIUS, a Longitudinal Observational, Multicenter Real-World Outcome Study in Patients with Relapsing-Remitting MS.
    Zivadinov R, Bergsland N, Korn JR, Dwyer MG, Khan N, Medin J, Price JC, Weinstock-Guttman B, Silva D, MS-MRIUS Study Group.
    AJNR Am J Neuroradiol; 2018 Feb; 39(2):289-295. PubMed ID: 29170269
    [Abstract] [Full Text] [Related]

  • 8. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis.
    Zivadinov R, Sepcic J, Nasuelli D, De Masi R, Bragadin LM, Tommasi MA, Zambito-Marsala S, Moretti R, Bratina A, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M.
    J Neurol Neurosurg Psychiatry; 2001 Jun; 70(6):773-80. PubMed ID: 11385012
    [Abstract] [Full Text] [Related]

  • 9. Neuroinflammation and its relationship to changes in brain volume and white matter lesions in multiple sclerosis.
    Datta G, Colasanti A, Rabiner EA, Gunn RN, Malik O, Ciccarelli O, Nicholas R, Van Vlierberghe E, Van Hecke W, Searle G, Santos-Ribeiro A, Matthews PM.
    Brain; 2017 Nov 01; 140(11):2927-2938. PubMed ID: 29053775
    [Abstract] [Full Text] [Related]

  • 10. Thalamic damage and long-term progression of disability in multiple sclerosis.
    Rocca MA, Mesaros S, Pagani E, Sormani MP, Comi G, Filippi M.
    Radiology; 2010 Nov 01; 257(2):463-9. PubMed ID: 20724544
    [Abstract] [Full Text] [Related]

  • 11. A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients.
    Zivadinov R, Uher T, Hagemeier J, Vaneckova M, Ramasamy DP, Tyblova M, Bergsland N, Seidl Z, Dwyer MG, Krasensky J, Havrdova E, Horakova D.
    Mult Scler; 2016 Nov 01; 22(13):1709-1718. PubMed ID: 26883943
    [Abstract] [Full Text] [Related]

  • 12. Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study.
    Horakova D, Dwyer MG, Havrdova E, Cox JL, Dolezal O, Bergsland N, Rimes B, Seidl Z, Vaneckova M, Zivadinov R.
    J Neurol Sci; 2009 Jul 15; 282(1-2):112-9. PubMed ID: 19168190
    [Abstract] [Full Text] [Related]

  • 13. Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.
    Zivadinov R, Hojnacki D, Bergsland N, Kennedy C, Hagemeier J, Melia R, Ramasamy DP, Durfee J, Carl E, Dwyer MG, Weinstock-Guttman B.
    Eur J Neurol; 2016 Jun 15; 23(6):1101-9. PubMed ID: 26998905
    [Abstract] [Full Text] [Related]

  • 14. Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study.
    Barnett M, Bergsland N, Weinstock-Guttman B, Butzkueven H, Kalincik T, Desmond P, Gaillard F, van Pesch V, Ozakbas S, Rojas JI, Boz C, Altintas A, Wang C, Dwyer MG, Yang S, Jakimovski D, Kyle K, Ramasamy DP, Zivadinov R.
    Neuroimage Clin; 2021 Jun 15; 32():102802. PubMed ID: 34469848
    [Abstract] [Full Text] [Related]

  • 15. Diffusely Abnormal White Matter, T2 Burden of Disease, and Brain Volume in Relapsing-Remitting Multiple Sclerosis.
    Vertinsky AT, Li DKB, Vavasour IM, Miropolsky V, Zhao G, Zhao Y, Riddehough A, Moore GRW, Traboulsee A, Laule C.
    J Neuroimaging; 2019 Jan 15; 29(1):151-159. PubMed ID: 30376195
    [Abstract] [Full Text] [Related]

  • 16. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis.
    Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R, Thompson AJ, Miller DH.
    Brain; 2008 Mar 15; 131(Pt 3):808-17. PubMed ID: 18234696
    [Abstract] [Full Text] [Related]

  • 17. Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study.
    Eijlers AJC, van Geest Q, Dekker I, Steenwijk MD, Meijer KA, Hulst HE, Barkhof F, Uitdehaag BMJ, Schoonheim MM, Geurts JJG.
    Brain; 2018 Sep 01; 141(9):2605-2618. PubMed ID: 30169585
    [Abstract] [Full Text] [Related]

  • 18. T2 lesions and rate of progression of disability in multiple sclerosis.
    Mostert JP, Koch MW, Steen C, Heersema DJ, De Groot JC, De Keyser J.
    Eur J Neurol; 2010 Dec 01; 17(12):1471-5. PubMed ID: 20500805
    [Abstract] [Full Text] [Related]

  • 19. Whole-brain N-acetylaspartate concentration: correlation with T2-weighted lesion volume and expanded disability status scale score in cases of relapsing-remitting multiple sclerosis.
    Bonneville F, Moriarty DM, Li BS, Babb JS, Grossman RI, Gonen O.
    AJNR Am J Neuroradiol; 2002 Mar 01; 23(3):371-5. PubMed ID: 11901002
    [Abstract] [Full Text] [Related]

  • 20. Can resistance training impact MRI outcomes in relapsing-remitting multiple sclerosis?
    Kjølhede T, Siemonsen S, Wenzel D, Stellmann JP, Ringgaard S, Pedersen BG, Stenager E, Petersen T, Vissing K, Heesen C, Dalgas U.
    Mult Scler; 2018 Sep 01; 24(10):1356-1365. PubMed ID: 28752800
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.